News

May 12, 2017

DUR-928 Developer Durect Joins with Sandoz on Posimir Pain Reliever System Efforts

News

Durect has signed an agreement with Sandoz to develop and market Posimir (Saber-bupivacaine), an investigational localized pain reliever, in the United States. Durect is working on several product candidates, including DUR-928 ... Read more

May 11, 2017May 12, 2017

Genkyotex’s GKT831 Drug Moves to Phase 2 Trial After Winning FDA Investigational New Drug Status

News

The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase 2 clinical trial in patients with ... Read more

May 10, 2017May 10, 2017

Novartis Exercises Option to Develop and Market Conatus’ Emricasan to Treat NASH

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed in December 2016, Novartis will obtain the license ... Read more

May 9, 2017

First Patient Enrolled in Phase 2 Clinical Trial of Elafibranor for Bile Duct Disease

News, Non-alcoholic steatohepatitis

GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary biliary cholangitis (PBC). The study is recruiting ... Read more

May 8, 2017

New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments

Alcoholic liver disease, Hepatitis, Liver cancer, Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver Line, patients and the community can learn ... Read more

May 5, 2017May 5, 2017

Can-Fite’s Namodenoson to Enter NAFLD/NASH Phase 2 Clinical Trial

Liver cancer, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will be conducted in two leading medical ... Read more

May 4, 2017

Singapore Researchers Develop Probe That Improves Liver Cancer MRI Imaging

Liver cancer, News

Researchers at the National University of Singapore have developed a probe that provides doctors with clearer and more accurate magnetic resonance images of liver cancer. The MRI tool will help doctors ... Read more

May 3, 2017May 12, 2017

Hepko-V5 Cancer Vaccine Boosts Survival Rates in Advanced Liver Cancer Patients, Mongolian Study Finds

Liver cancer, News

Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial. More than 90 percent of the ... Read more

May 2, 2017May 12, 2017

New Study Is Examining How Doctors Manage Patients with Liver Disease

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the study in collaboration with the biopharmaceutical company Allergan. ... Read more

April 28, 2017May 12, 2017

FDA Approves Stivarga as Treatment for Common Form of Liver Cancer

Liver cancer, News

The U.S. Food and Drug Administration (FDA) approved the use of Stivarga (regorafinib) for the treatment of patients with hepatocellular carcinoma (HCC), a form of liver cancer, who progressed after ... Read more